UP!
 |
|
|
Type
|
Public company |
|---|---|
| Traded as | NASDAQ: AGTC |
| Industry | Biotechnology |
| Founded | 1999 |
| Headquarters | Alachua, Florida |
| Website | www |
The Applied Genetic Technologies Corporation is a publicly traded (NASDAQ:AGTC) biotechnology company that is part of the NASDAQ Biotechnology Index. It was founded in 1999 and has its headquarters in Alachua, Florida.
The company focuses on ophthalmologic genetic diseases. The company's technologies are aimed at products that might have the potential to treat achromatopsia, X-linked retinoschisis, X-linked retinitis pigmentosa, and age-related macular degeneration. The company has six products in various stages of development; as of 2016, none had yet been approved.
| Period | Date | Adjusted Actuals EPS | GAAP EPS |
|---|---|---|---|
| Q1 2023 | 2022-11-14 | Future report Set alerts | |
| Q4 2022 | 2022-09-16 | Future report Set alerts | |
| Q3 2022 | 2022-05-16 | -0.33 | -0.33 |
| Q2 2022 | 2022-02-14 | -0.45 | -0.45 |
| Q1 2022 | 2021-11-09 | -0.40 | -0.40 |
| Q4 2021 | 2021-09-23 | -0.28 | -0.28 |
| Q3 2021 | 2021-05-17 | -0.40 | -0.40 |
| Q2 2021 | 2021-02-11 | -0.60 | -0.60 |
| Q1 2021 | 2020-11-11 | 0.00 | 0.00 |
| Q4 2020 | 2020-09-09 | -0.56 | -0.56 |
| 2016-06-22 | Reiterated Rating | Cantor Fitzgerald | Buy | $32.00 |
| 2016-05-10 | Reiterated Rating | Wedbush | Outperform | $36.00 |
| 2016-05-10 | Reiterated Rating | Wells Fargo | Buy | |
| 2016-05-10 | Reiterated Rating | Cantor Fitzgerald | Buy | $32.00 |
| 2016-05-10 | Reiterated Rating | Wells Fargo & Co. | Buy | |
| 2016-04-25 | Reiterated Rating | Roth Capital | Buy | |
| 2016-04-11 | Initiated Coverage | BMO Capital Markets | Outperform | $25.00 |
| 2016-03-18 | Initiated Coverage | Janney Montgomery Scott | Buy | $23.00 |
| 2016-02-09 | Lower Price Target | Stifel Nicolaus | Buy | $32.00 to $29.00 |
| 2016-02-09 | Reiterated Rating | Cantor Fitzgerald | Buy | $32.00 |
| 2016-01-10 | Reiterated Rating | Chardan Capital | Buy | $25.00 |
| 2015-12-17 | Reiterated Rating | Cantor Fitzgerald | Buy | $32.00 |
| 2015-12-11 | Reiterated Rating | Cantor Fitzgerald | Buy | $32.00 |
| 2015-12-03 | Initiated Coverage | Wells Fargo | Outperform | |
| 2015-10-05 | Reiterated Rating | Cantor Fitzgerald | Buy to Buy | $32.00 |
| 2015-09-11 | Reiterated Rating | Roth Capital | Buy | $34.00 |
| 2015-09-11 | Reiterated Rating | Wedbush | Outperform | $36.00 |
| 2015-09-11 | Reiterated Rating | Cantor Fitzgerald | Buy | $32.00 |
| 2015-08-30 | Reiterated Rating | Chardan Capital | Buy | $25.00 |
| 2015-08-28 | Reiterated Rating | Roth Capital | Buy | $34.00 |
| 2015-07-22 | Initiated Coverage | Chardan Capital | Buy | $25.00 |
| 2015-07-06 | Boost Price Target | Cantor Fitzgerald | Buy | $28.00 to $32.00 |
| 2015-07-03 | Reiterated Rating | BMO Capital Markets | Outperform | $34.00 to $42.00 |
| 2015-07-02 | Reiterated Rating | Roth Capital | Buy | $34.00 |
| 2015-06-23 | Set Price Target | Wedbush | Buy | $36.00 |
| 2015-06-23 | Set Price Target | Roth Capital | Buy | $34.00 |
| 2015-06-23 | Reiterated Rating | Cantor Fitzgerald | Buy | $28.00 |
| 2015-05-05 | Set Price Target | Roth Capital | Buy | $34.00 |
| 2015-05-05 | Set Price Target | Cantor Fitzgerald | Buy | $28.00 |
| 2015-03-26 | Reiterated Rating | Cantor Fitzgerald | Buy | $28.00 |
| 2015-03-11 | Reiterated Rating | Cantor Fitzgerald | Buy | $28.00 |
| 2015-02-12 | Reiterated Rating | Cantor Fitzgerald | Buy | $28.00 |
| 2014-11-13 | Reiterated | ROTH Capital | Buy | $25 to $34 |
| 2014-11-13 | Boost Price Target | Cantor Fitzgerald | Buy | $24.00 to $28.00 |
| 2014-11-13 | Boost Price Target | Stifel Nicolaus | Buy | $29.00 to $31.00 |
| 2014-11-13 | Boost Price Target | Roth Capital | Buy | $25.00 to $34.00 |
| 2014-10-03 | Reiterated Rating | Wunderlich | Buy | $29.00 |
| 2014-10-03 | Initiated Coverage | Stifel Nicolaus | Buy | $29.00 |
| 2014-08-21 | Boost Price Target | Cantor Fitzgerald | Buy | $21.00 to $24.00 |
| 2014-06-09 | Boost Price Target | BMO Capital Markets | Outperform | $21.00 to $34.00 |
| 2014-04-21 | Initiated Coverage | Roth Capital | Buy | |
| 2014-04-21 | Initiated Coverage | Wedbush | Outperform | |
| 2014-04-21 | Initiated Coverage | Cantor Fitzgerald | Buy | $21.00 |
| 2014-04-21 | Initiated Coverage | BMO Capital Markets | Outperform | $14.08 |
| 2016-06-22 | Reiterated Rating | Cantor Fitzgerald | Buy | $32.00 |
| 2016-05-10 | Reiterated Rating | Wedbush | Outperform | $36.00 |
| 2016-05-10 | Reiterated Rating | Wells Fargo | Buy | |
| 2016-05-10 | Reiterated Rating | Cantor Fitzgerald | Buy | $32.00 |
| 2016-05-10 | Reiterated Rating | Wells Fargo & Co. | Buy |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In AGTC 0 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|
| Name Relationship | Total Shares | Holding stocks |
|---|---|---|
| Carroll Jill | 14.13% (1989598) | AGTC / |
| Alta Partners VIII, L.P. | 10.60% (1492200) | AGTC / ESPR / IMDZ / NEOT / TRVN / ZSPH / |
| INTERWEST PARTNERS VIII LP | 10.32% (1452216) | AGTC / MGNX / |
| MedImmune Ventures, Inc. | 10.32% (1452196) | AGTC / |
| Wu Samuel | 10.32% (1452196) | AGTC / |
| GLAXOSMITHKLINE PLC | 10.20% (1436448) | AGTC / CNCE / FOLD / GNCA / OMED / PATH / TBPH / THRX / |
| Rosen James | 8.56% (1205537) | AGTC / |
| Feinsod Matthew Interim Chief Medical Officer | 0.28% (39377) | AGTC / |
| ORONSKY ARNOLD L | 0.08% (11208) | AGTC / DVAX / MGNX / TSRO / |
| Chulay Jeffrey D. V.P. & Chief Medical Officer | 0.07% (9900) | AGTC / |
| HURWITZ EDWARD | 0.01% (1800) | AGTC / CARA / MGNX / SNSS / |
UM